Brand Reference: Maxalt, Maxalt-MLT
| Metric | Verified Benchmark | Source |
|---|---|---|
| Rizatriptan Benzoate Orally Disintegrating (ODT) RxNorm Concept ID | 88014 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $86.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $7.60 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $9.80 / mo | 31 Zero-PHI Verified Patient Logs |
Engineered with 3x higher oral bioavailability and faster CNS/trigeminal Cmax than oral sumatriptan, suppressing dural calcitonin gene-related peptide (CGRP) extravasation for rapid 2-hour pain-free migraine termination.
For self-pay patients filling Rizatriptan Benzoate Orally Disintegrating (ODT) (NDC 00378-3682-77), direct wholesale and telehealth fulfillment drops monthly spend from $86.00 retail to $7.60 (91% savings against a $0.3900 CMS pharmacy acquisition baseline).
Clinical clearance of Rizatriptan Benzoate Orally Disintegrating (ODT) (Fast-Tmax Lipophilic 5-HT1B / 5-HT1D Trigeminal Agonist) relies on mao-a oxidative deamination (note: propranolol raises rizatriptan auc 70%—use 5 mg max with propranolol) with a 2–3 hours half-life; patients absorbing at 45% oral (3x oral sumatriptan) bioavailability typically observe target onset around 30–45 minutes.
FDA clinical labeling for Rizatriptan Benzoate Orally Disintegrating (ODT) restricts administration in ischemic heart disease or uncontrolled hypertension; hemiplegic migraine; maoi within 14 days across 5 mg ODT/PO at onset (mandatory cap if on propranolol), 10 mg ODT/PO at onset, with self-reported patient tracking dominated by neck heaviness (15% of reports), somnolence (14% of reports), dry mouth (9% of reports).
Across 31 verified cash-pay logs, Rizatriptan Benzoate Orally Disintegrating (ODT) achieves a 93.20% Worth-It rating with out-of-pocket spend averaging $9.80/mo versus $86.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 5 mg ODT/PO at onset (mandatory cap if on propranolol) for Rizatriptan Benzoate Orally Disintegrating (ODT); monthly out-of-pocket dropped to $6.69 compared with $86.00 retail.
Completed 10 weeks on Rizatriptan Benzoate Orally Disintegrating (ODT) (10 mg ODT/PO at onset). Zero notable side effects on steady dosing.
Consistent biomarker response on 5 mg ODT/PO at onset (mandatory cap if on propranolol) Rizatriptan Benzoate Orally Disintegrating (ODT) sourced via Compounding ($8.82/mo cash pay without insurance prior authorization).